Hypocalcaemia and hospitalization after initiation of bone-modifying agents in dialysis patients
Open Access
- 2 November 2026
- journal article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (11)
Abstract
Background and hypothesis: Bone-modifying agents are associated with hypocalcaemia in dialysis patients, leading to serious adverse consequences. We examined factors associated with all-cause hospitalization, longitudinal serum calcium trajectories by medication class, and baseline predictors of hypocalcaemia in dialysis patients initiating bone-modifying agents. Methods: Using the JMDC hospital database, we identified dialysis patients newly prescribed bisphosphonates, denosumab, teriparatide, or romosozumab. Factors associated with all-cause hospitalization were examined using Cox regression. Serum calcium trajectories were assessed over 90 days before and after treatment initiation. Factors associated with hypocalcaemia (corrected calcium <8.0 mg/dl) within 90 days were analysed. Results: Among 2020 patients on dialysis, 1057 (52.3%) received bisphosphonates; 693 (34.3%), denosumab; 136 (6.7%), teriparatide; and 134 (6.6%), romosozumab. Hospitalization occurred in 425 patients, and recent hospitalization and pretreatment lower corrected serum calcium levels were associated with hospitalization, with no significant differences across medications. Among 374 patients with laboratory data, post-treatment hypocalcaemia occurred in 99 (26.5%). Persistent reductions in serum calcium levels were observed after initiating denosumab or romosozumab. Adjusted odds ratios (OR) for post-treatment hypocalcaemia were 13.4 (6.90–26.1) for denosumab and 8.09 (2.20–29.8) for romosozumab. Pretreatment calcium and parathyroid hormone levels were associated with post-treatment hypocalcaemia [adjusted ORs: 0.29 (0.18, 0.49) and 1.59 (1.05, 2.39), respectively]. Conclusion: In dialysis patients, denosumab and romosozumab were associated with a higher risk of post-treatment hypocalcaemia than bisphosphonates, and pretreatment lower calcium was associated with hospitalization. Our findings highlight the importance of optimizing parathyroid hormone management and enhancing calcium monitoring when initiating bone-modifying agents.Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 30 references indexed in Scilit:
- Chronic kidney disease–mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceKidney International, 2025
- Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent PatientsJAMA, 2024
- Alkaline Phosphatase and Parathyroid Hormone Levels: International Variation and Associations With Clinical Outcomes in the DOPPSKidney International Reports, 2024
- Manejo de la osteoporosis en el paciente con enfermedad renal crónica (Estudio ERCOS): un desafío en la asistencia nefrológicaNefrología, 2023
- Hypocalcemia Risk of Denosumab Across the Spectrum of Kidney Disease: A Population-Based Cohort StudyJournal of Bone and Mineral Research, 2020
- Data resource profile: JMDC claims databases sourced from Medical InstitutionsJournal of General and Family Medicine, 2020
- Major fractures after initiation of dialysis: Incidence, predictors and association with mortalityBone, 2020
- Anti-Sclerostin Antibody Treatment in a Rat Model of Progressive Renal OsteodystrophyJournal of Bone and Mineral Research, 2014
- Epidemiology and mortality of hip fracture among patients on dialysis: Taiwan National Cohort StudyBone, 2014
- Increased risk of hip fracture among Japanese hemodialysis patientsJournal of Bone and Mineral Metabolism, 2013